# Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP)

> **NCT00154271** · PHASE4 · COMPLETED · sponsor: **Novartis** · enrollment: 1677 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Valsartan, Valsartan HCT

## Key facts

- **NCT ID:** NCT00154271
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2005-06
- **Final completion:** 2005-06
- **Target enrollment:** 1677 (ACTUAL)
- **Last updated:** 2011-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00154271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00154271, "Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00154271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*